There is an ongoing need for high-precision serological assays for the quantitation of
anti-SARS-CoV-2 antibodies. Here, a trimeric SARS-CoV-2 spike (S) protein was used to develop an
ELISA to quantify specific IgG antibodies present in serum, plasma, and dried blood spots (DBS)
collected from infected patients or vaccine recipients. The quantitative S-ELISA was calibrated with
international anti-SARS-CoV-2 immunoglobulin standards to provide test results in binding antibody
units per mL (BAU/mL). The assay showed excellent linearity, precision, and accuracy. A sensitivity
of 100% was shown for samples collected from 54 patients with confirmed SARS-CoV-2 infection more
than 14 days after symptom onset or disease confirmation by RT-PCR and 58 vaccine recipients more
than 14 days after vaccination. The assay specificity was 98.3%. Furthermore, antibody responses
were measured in follow-up samples from vaccine recipients and infected patients. Most mRNA
vaccine recipients had a similar response, with antibody generation starting 2–3 weeks after the first
vaccination and maintaining positive for at least six months after a second vaccination. For most
infected patients, the antibody titers increased during the second week after PCR confirmation. This
S-ELISA can be used to quantify the seroprevalence of SARS-CoV-2 in the population exposed to the
virus or vaccinated.
| Identifer | oai:union.ndltd.org:DRESDEN/oai:qucosa:de:qucosa:90508 |
| Date | 14 March 2024 |
| Creators | Luo, Ji, Klett, Jennifer, Gabert, Jörg, Lipp, Thomas, Karbach, Julia, Jäger, Elke, Borte, Stephan, Hoffmann, Ralf, Milkovska-Stamenova, Sanja |
| Publisher | MDPI |
| Source Sets | Hochschulschriftenserver (HSSS) der SLUB Dresden |
| Language | English |
| Detected Language | English |
| Type | info:eu-repo/semantics/publishedVersion, doc-type:article, info:eu-repo/semantics/article, doc-type:Text |
| Rights | info:eu-repo/semantics/openAccess |
| Relation | 1812, 10.3390/microorganisms10091812 |
Page generated in 0.0022 seconds